Overview
Communication breakdown in Alzheimer’s disease (AD) reflects underlying cognitive deterioration and directly impacts daily function, independence, and social connection. Redenlab’s speech and language-based endpoints offer sensitive, ecologically valid measures to support clinical trial outcomes that matter to patients, families, clinicians and regulators.
Core symptomatology of AD is reflected in altered communication
Alzheimer’s disease affects over 55 million people worldwide, with communication decline emerging early and worsening as the disease progresses. Difficulties with word-finding, fluency, and conversational ability can isolate individuals, reduce autonomy, and undermine quality of life, sometimes before functional loss is captured on traditional cognitive scales. These changes often go unmeasured in trials despite being highly meaningful to patients and caregivers. Redenlab delivers digital speech and language assessments that capture these real-world sequelae, enabling scalable, objective tracking of functional decline and response to therapy.
Meaningful speech and language-based outcomes for AD trials
Real-world relevance
Early and progressive signal
Validated in at-risk and prodromal populations
Low-burden, high-frequency assessment
Aligned with patient-centred outcomes
Redenlab’s AD experience
NUMBER OF STUDIES
PATIENTS ASSESSED
Redenlab are partnering with academic colleagues at the University of Rhode Island in their Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS) examining multiple digital and clinical biomarkers over time. This work has supported efforts to link meaningful outcomes like speech to underlying biological markers (e.g. p-tau217, NfL).
